Innovation Pharmaceuticals Inc (IPIX)

[williamssc]

Eighth paragraph--
We’ve had a very successful launch of POMALYST in the U.S. we now are into our second year with that product going with its first full year impact in the U.S. this year are in the middle of the launch for the product its straight down of IMNOVID in Europe and it has been even more successful than we expected it to be trajectory is very strong and you could see some of the things going on there. We also have plans to study the product in combination with proteasome inhibitors, monoclonal antibodies or HDAC inhibitors also with the view to potentially moving it up into second line therapy and again life cycle of the product creates the most value with that.

http://finance.yahoo.com/news/celgenes-management-presents-sanford-c-004609823.html